Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within...

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Malignant pediatric brain tumors like medulloblastoma often have low mutation rates, complicating the identification of therapeutic targets.
• Understanding post-transcriptional and post-translational regulation is crucial for developing effective cancer therapies.

Purpose of the Study:

• To quantitatively profile global proteomes and phospho-proteomes in medulloblastoma to uncover novel therapeutic strategies.
• To investigate molecular differences at the protein level in medulloblastoma subtypes, particularly those with low mutation rates.

Main Methods:

• Quantitative proteomic and phospho-proteomic profiling of 45 medulloblastoma patient samples.
• Integrated analysis of proteomic data with existing RNA expression data.
• Functional assays to test the impact of kinase inhibition on cancer cell sensitivity.

Main Results:

• Significant variations in post-transcriptional and post-translational profiles were observed even among tumors with similar RNA expression.
• Distinct molecular pathways were identified in two subsets of SHH medulloblastoma.
• Post-translational modifications of MYC were linked to poor outcomes in group 3 medulloblastoma.
• Specific kinases were associated with medulloblastoma subtypes, and PRKDC inhibition sensitized MYC-driven cells to radiation.

Conclusions:

• Proteomics provides a comprehensive, functional readout essential for understanding medulloblastoma biology.
• The study identifies potential therapeutic targets and strategies, including PRKDC inhibition, for medulloblastoma treatment.
• These findings lay the groundwork for developing novel therapeutic approaches for challenging pediatric brain tumors.